Last reviewed · How we verify
Androgen deprivation treatment
Androgen deprivation treatment is a Hormone antagonist Small molecule drug developed by baotai Liang. It is currently in Phase 2 development for Prostate cancer, Breast cancer in men.
Androgen deprivation treatment drugs work by reducing the production of androgens, such as testosterone, which can fuel the growth of certain types of cancer.
Androgen deprivation treatment drugs work by reducing the production of androgens, such as testosterone, which can fuel the growth of certain types of cancer. Used for Prostate cancer, Breast cancer in men.
At a glance
| Generic name | Androgen deprivation treatment |
|---|---|
| Sponsor | baotai Liang |
| Drug class | Hormone antagonist |
| Target | Androgen receptors |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 2 |
Mechanism of action
Androgen deprivation therapy (ADT) is a type of hormone therapy that involves blocking the production of androgens, which are male hormones that can contribute to the growth and spread of cancer cells. By reducing androgen levels, ADT can help slow or stop the growth of cancer cells, making it easier to treat the disease.
Approved indications
- Prostate cancer
- Breast cancer in men
Common side effects
- Hot flashes
- Fatigue
- Osteoporosis
- Infertility
Key clinical trials
- A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (PHASE2)
- A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer (PHASE1, PHASE2)
- Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment (PHASE3)
- High-Risk prostatE Cancer radiatiOn Versus surgERy
- An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC. (PHASE3)
- PRO-BOOST-N: Prostate-First Versus Combined Prostate and Nodal Dose Escalation in PSMA PET-Staged Node-Positive Prostate Cancer (PHASE2, PHASE3)
- SUPERvised Three-month Exercise Program in MEN With Prostate cAncer Receiving Androgen-deprivaTioN thERapy (NA)
- Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Androgen deprivation treatment CI brief — competitive landscape report
- Androgen deprivation treatment updates RSS · CI watch RSS
- baotai Liang portfolio CI
Frequently asked questions about Androgen deprivation treatment
What is Androgen deprivation treatment?
How does Androgen deprivation treatment work?
What is Androgen deprivation treatment used for?
Who makes Androgen deprivation treatment?
What drug class is Androgen deprivation treatment in?
What development phase is Androgen deprivation treatment in?
What are the side effects of Androgen deprivation treatment?
What does Androgen deprivation treatment target?
Related
- Drug class: All Hormone antagonist drugs
- Target: All drugs targeting Androgen receptors
- Manufacturer: baotai Liang — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Prostate cancer
- Indication: Drugs for Breast cancer in men
- Compare: Androgen deprivation treatment vs similar drugs
- Pricing: Androgen deprivation treatment cost, discount & access